sb 203580 has been researched along with olmesartan in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 841 | 185 | 554 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ito, S; Kyotani, Y; Nagayama, K; Ozawa, K; Yoshizumi, M; Zhao, J | 1 |
1 other study(ies) available for sb 203580 and olmesartan
Article | Year |
---|---|
Olmesartan inhibits cultured rat aortic smooth muscle cell death induced by cyclic mechanical stretch through the inhibition of the c-Jun N-terminal kinase and p38 signaling pathways.
Topics: Animals; Anthracenes; Cell Death; Cells, Cultured; Enzyme Inhibitors; Imidazoles; JNK Mitogen-Activated Protein Kinases; Male; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Rats; Signal Transduction; Stress, Mechanical; Tetrazoles | 2015 |